Polymyositis and dermatomyositis laboratory findings: Difference between revisions
Line 35: | Line 35: | ||
|- | |- | ||
|Histidyl-tRNA synthetase (anti-Jo-1) | |Histidyl-tRNA synthetase (anti-Jo-1) | ||
| | |myositis, interstitial lung disease, mechanic’s hands, and arthritis | ||
| | |Antisynthetase syndrome | ||
| | | | ||
| | | |
Revision as of 15:54, 5 April 2018
Polymyositis and dermatomyositis Microchapters |
Differentiating Polymyositis and dermatomyositis from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Polymyositis and dermatomyositis laboratory findings On the Web |
American Roentgen Ray Society Images of Polymyositis and dermatomyositis laboratory findings |
Polymyositis and dermatomyositis laboratory findings in the news |
Blogs on Polymyositis and dermatomyositis laboratory findings |
Risk calculators and risk factors for Polymyositis and dermatomyositis laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Overview
An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].
OR
Laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
OR
[Test] is usually normal for patients with [disease name].
OR
Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].
OR
There are no diagnostic laboratory findings associated with [disease name].
Laboratory Findings
- Laboratory findings consistent with the diagnosis of polymyositis and dermatomyositis include:[1]
Myositis-specific autoantibodies
Autoantibody | Effect | Association | Percentage | |
---|---|---|---|---|
Histidyl-tRNA synthetase (anti-Jo-1) | myositis, interstitial lung disease, mechanic’s hands, and arthritis | Antisynthetase syndrome | ||
Chromodomain helicase DNA binding protein 4 (Mi-2) | ||||
Signal recognition particle (anti-SRP) | ||||
Alanyl-tRNA synthetase (PL-12) | ||||
Transcriptional intermediary factor 1-gamma (TIF-1γ) | ||||
Nuclear matrix protein (NXP-2) | ||||
Anti-small ubiquitin-like modifier activating enzyme (anti-SAE) | ||||
Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) | immune-mediated necrotizing myopathies | statin-associated necrotizing autoimmune myopathy (SANAM) | 6% | |